BTIG Research Reiterates “Buy” Rating for Maze Therapeutics (NASDAQ:MAZE)

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They presently have a $46.00 target price on the stock. BTIG Research’s target price indicates a potential upside of 2.61% from the company’s previous close.

Other research analysts have also issued reports about the company. Wells Fargo & Company assumed coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 target price on the stock. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Raymond James Financial assumed coverage on shares of Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price for the company. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, HC Wainwright reiterated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Maze Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $48.57.

Maze Therapeutics Trading Down 1.0%

Shares of MAZE opened at $44.83 on Monday. The firm has a market cap of $2.16 billion, a PE ratio of -2.14 and a beta of 4.47. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $49.25. The stock has a fifty day moving average price of $43.91 and a 200-day moving average price of $34.63.

Insiders Place Their Bets

In other Maze Therapeutics news, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider directly owned 10,503 shares in the company, valued at approximately $426,001.68. The trade was a 87.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 200,000 shares of company stock valued at $8,254,792.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors have recently modified their holdings of MAZE. Frazier Life Sciences Management L.P. lifted its holdings in shares of Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after buying an additional 438,274 shares during the period. Janus Henderson Group PLC grew its holdings in Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after acquiring an additional 2,390,713 shares during the period. Vanguard Group Inc. lifted its holdings in Maze Therapeutics by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after acquiring an additional 362,060 shares during the period. Woodline Partners LP boosted its position in Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after purchasing an additional 94,529 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Maze Therapeutics by 9.0% in the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock worth $35,111,000 after purchasing an additional 69,771 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.